Defining the signaling mechanisms of lymphocyte activation gene-3 (LAG-3) in T cells

International Congress on Neuroimmunology and Therapeutics

DoubleTree by Hilton Hotel San Francisco Airport, San Francisco, CA, USA

Naif Ali Alhumeed, Thilipan Thaventhiran, Kevin Park and Jean Sathish

Posters-Accepted Abstracts: J Neurol Disord

Abstract :

Background: Lymphocyte activation gene-3 (LAG-3) is an inhibitory receptor expressed on activated T cells, B cell, and Natural Killer cells. LAG-3 is engaged by MHC class II molecules expressed by antigen presenting cells (such as dendritic cells) which lead to T cell inhibition. It is one of the main targets in immune therapy. Several studies are currently exploring the enhancement T cell proliferation via the blockage of LAG3 or combining with other receptor blockage. However, the molecular mechanism of this is yet unclear. Aim: The broad aim of our research is to define the signalling pathways that are modulated by LAG-3. The specific aim for the initial part of our research is to establish a DC-T cell antigen specific experimental system that will enable analysis of key T cell signalling pathways. Results: We demonstrate that a mouse transgenic T cell receptor model (F5 TCR transgenic mouse) when coupled with dendritic cells that express the correct antigen is an appropriate model to examine LAG-3 signalling. Our results reveal induction of tyrosine phosphorylation in several T cell proteins and identify a potential candidate target of LAG-3 modulation. Conclusion: The F5 TCR transgenic and dendritic cell mouse experimental system is useful for signalling studies on LAG-3.